CongressTrades

REGN

PHARMACEUTICAL PREPARATIONS

Regeneron Pharmaceuticals, Inc. - Common Stock (REGN) [ST]

www.regeneron.com ↗
$602.92

▼ 0.48%

prev close

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Congressional Trades

14

All tracked trades

Members Trading

7

Unique members

Net Activity

-6

4 buys · 10 sells

Members Who Traded This Stock

14 trade events

2025-11-18

Gilbert Cisneros

REGN

Buy

Amount

$1,001 - $15,000

Filed

170d ago

2025-04-08

Rob Bresnahan

REGN

Sell

Amount

$1,001 - $15,000

Filed

391d ago

2025-04-07

Jefferson Shreve

REGN

Sell

Amount

$15,001 - $50,000

Filed

391d ago

2025-02-12

Julie Johnson

REGN

Sell

Amount

$1,001 - $15,000

Filed

448d ago

2025-01-24

Josh Gottheimer

REGN

Sell

Amount

$1,001 - $15,000

Filed

478d ago

2025-01-15

Julie Johnson

REGN

Buy

Amount

$1,001 - $15,000

Filed

476d ago

2024-11-19

Josh Gottheimer

REGN

Sell

Amount

$1,001 - $15,000

Filed

545d ago

2024-11-13

Jonathan Jackson

REGN

Sell

Amount

$15,001 - $50,000

Filed

538d ago

2024-10-15

Greg Landsman

REGN

Sell

Amount

$1,001 - $15,000

Filed

566d ago

2023-11-13

Josh Gottheimer

REGN

Sell

Amount

$1,001 - $15,000

Filed

908d ago

2023-08-21

Josh Gottheimer

REGN

Buy

Amount

$1,001 - $15,000

Filed

991d ago

2023-07-11

Josh Gottheimer

REGN

Buy

Amount

$1,001 - $15,000

Filed

1017d ago

2023-06-22

Josh Gottheimer

REGN

Sell

Amount

$1,001 - $15,000

Filed

1058d ago

2023-03-06

Josh Gottheimer

REGN

Sell

Amount

$1,001 - $15,000

Filed

1140d ago

Recent News

Powered by Polygon.io

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

GlobeNewswire Inc.·2026-06-03

Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight

GlobeNewswire Inc.·2026-06-02

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

GlobeNewswire Inc.·2026-05-28

Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing

The Motley Fool·2026-05-26

CytomX Therapeutics to Present at Upcoming June Investor Conferences

GlobeNewswire Inc.·2026-05-21

Trade Timeline

Congressional activity, newest first

Gilbert Cisneros

2025-11-18 · Purchase

$1,001 - $15,000

Rob Bresnahan

2025-04-08 · Sale

$1,001 - $15,000

Jefferson Shreve

2025-04-07 · Sale

$15,001 - $50,000

Julie Johnson

2025-02-12 · Sale

$1,001 - $15,000

Josh Gottheimer

2025-01-24 · Sale

$1,001 - $15,000

Julie Johnson

2025-01-15 · Purchase

$1,001 - $15,000

Josh Gottheimer

2024-11-19 · Sale

$1,001 - $15,000

Jonathan Jackson

2024-11-13 · Sale

$15,001 - $50,000

Greg Landsman

2024-10-15 · Sale

$1,001 - $15,000

Josh Gottheimer

2023-11-13 · Sale

$1,001 - $15,000

Josh Gottheimer

2023-08-21 · Purchase

$1,001 - $15,000

Josh Gottheimer

2023-07-11 · Purchase

$1,001 - $15,000

Josh Gottheimer

2023-06-22 · Sale

$1,001 - $15,000

Josh Gottheimer

2023-03-06 · Sale

$1,001 - $15,000